Scholars@Duke
Paul Robert Conkling

Paul Robert Conkling

Consulting Associate in the Department of Medicine
Medicine, Medical Oncology
paul.conkling@usoncology.com
250W Brambleton #203, Norfolk, VA 23510
Manage Profile
Embed Profile Data

Selected Publications

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.

Journal Article Ann Oncol · May 2020 BACKGROUND: This phase Ib study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of the oral AKT inhibitor ipatasertib and chemotherapy or hormonal therapy in patients with advanced or metastatic solid tumors to determine comb ... Full text Link to item Cite

A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · February 20, 2018 187 Background: In the past decade, several therapies have been approved for mCRPC. However, most pts develop resistance and experience disease progression. Thus, there remains a high unmet need. Atezo (anti–PD-L1) blocks the int ... Full text Cite

Abstract P4-13-25: Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer

Conference Cancer Research · February 15, 2016 AbstractBackground: Abemaciclib, a small molecule inhibitor of CDK4 and CDK6, induces G1 cell cycle arrest in Rb-proficient human cancers.1 The clinical safety profile of abemaciclib enables continuous oral ... Full text Cite

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.

Journal Article Eur J Cancer · September 2015 BACKGROUND: For patients with metastatic pancreatic adenocarcinoma, there are no approved or established treatments beyond the 2nd line. A Phase Ib study of fractionated radioimmunotherapy was undertaken in this setting, administering (90)Y-clivatuzumab te ... Full text Link to item Cite

Abstract B98: Final results of a randomized phase Ib study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having at least two prior therapies

Conference Cancer Research · July 1, 2015 AbstractBackground: Prior clinical studies in the first and second line setting showed radioimmunotherapy (RAIT) is a promising therapy for pancreatic cancer that avoids the side effects of further chemother ... Full text Cite

An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.

Journal Article Invest New Drugs · February 2015 BACKGROUND: This phase Ib study used a parallel, multi-arm design to examine tasisulam-sodium (hereafter tasisulam), a drug with complex pharmacology, combined with standard chemotherapies in patients with advanced solid tumors, with the ultimate goal of a ... Full text Link to item Cite

Thrombosis in acute promyelocytic leukemia.

Journal Article Thromb Res · April 2013 INTRODUCTION: Compared to bleeding, major thromboses are a less commonly encountered problem in acute promyelocytic leukemia (APL), and our knowledge about the epidemiology of major thromboses in APL stems mainly from individual case reports. The purpose o ... Full text Link to item Cite

Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.

Journal Article Clin Colorectal Cancer · June 2012 BACKGROUND: Cetuximab (C), alone or with irinotecan, demonstrates activity in irinotecan-refractory colorectal cancer (CRC). Activity of 5-fluorouracil (5-FU), leucovorin (L), and bevacizumab (B), and preliminary data of cetuximab + bevacizumab, and toxici ... Full text Link to item Cite

Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.

Journal Article Breast Cancer Res Treat · February 2011 Palliation is the primary goal in metastatic breast cancer (MBC), and safe, efficacious, new single-agent options are needed. Pemetrexed, an antifolate, inhibits several folate-dependent enzymes involved in purine biosynthesis. The primary goal of this stu ... Full text Link to item Cite

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors.

Journal Article Ann Oncol · May 2020 BACKGROUND: This phase Ib study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of the oral AKT inhibitor ipatasertib and chemotherapy or hormonal therapy in patients with advanced or metastatic solid tumors to determine comb ... Full text Link to item Cite

A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Conference Journal of Clinical Oncology · February 20, 2018 187 Background: In the past decade, several therapies have been approved for mCRPC. However, most pts develop resistance and experience disease progression. Thus, there remains a high unmet need. Atezo (anti–PD-L1) blocks the int ... Full text Cite

Abstract P4-13-25: Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer

Conference Cancer Research · February 15, 2016 AbstractBackground: Abemaciclib, a small molecule inhibitor of CDK4 and CDK6, induces G1 cell cycle arrest in Rb-proficient human cancers.1 The clinical safety profile of abemaciclib enables continuous oral ... Full text Cite

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.

Journal Article Eur J Cancer · September 2015 BACKGROUND: For patients with metastatic pancreatic adenocarcinoma, there are no approved or established treatments beyond the 2nd line. A Phase Ib study of fractionated radioimmunotherapy was undertaken in this setting, administering (90)Y-clivatuzumab te ... Full text Link to item Cite

Abstract B98: Final results of a randomized phase Ib study of fractionated 90Y-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having at least two prior therapies

Conference Cancer Research · July 1, 2015 AbstractBackground: Prior clinical studies in the first and second line setting showed radioimmunotherapy (RAIT) is a promising therapy for pancreatic cancer that avoids the side effects of further chemother ... Full text Cite

An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.

Journal Article Invest New Drugs · February 2015 BACKGROUND: This phase Ib study used a parallel, multi-arm design to examine tasisulam-sodium (hereafter tasisulam), a drug with complex pharmacology, combined with standard chemotherapies in patients with advanced solid tumors, with the ultimate goal of a ... Full text Link to item Cite

Thrombosis in acute promyelocytic leukemia.

Journal Article Thromb Res · April 2013 INTRODUCTION: Compared to bleeding, major thromboses are a less commonly encountered problem in acute promyelocytic leukemia (APL), and our knowledge about the epidemiology of major thromboses in APL stems mainly from individual case reports. The purpose o ... Full text Link to item Cite

Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.

Journal Article Clin Colorectal Cancer · June 2012 BACKGROUND: Cetuximab (C), alone or with irinotecan, demonstrates activity in irinotecan-refractory colorectal cancer (CRC). Activity of 5-fluorouracil (5-FU), leucovorin (L), and bevacizumab (B), and preliminary data of cetuximab + bevacizumab, and toxici ... Full text Link to item Cite

Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.

Journal Article Breast Cancer Res Treat · February 2011 Palliation is the primary goal in metastatic breast cancer (MBC), and safe, efficacious, new single-agent options are needed. Pemetrexed, an antifolate, inhibits several folate-dependent enzymes involved in purine biosynthesis. The primary goal of this stu ... Full text Link to item Cite

Novel organic arsenic molecule darinaparsin: Development of IV and oral forms.

Journal Article J Clin Oncol · May 20, 2009 8501 Background: Darinaparsin (ZIO-101) is a novel organic arsenical active against diverse cancers in vitro, and in vivo. Darinaparsin i.v. activity in lymphoma is being evaluated in a phase II study. Darinaparsin is orally bioavailable; the oral form is ... Link to item Cite

Sphingosine inhibits monocyte tissue factor-initiated coagulation by altering factor VII binding.

Journal Article J Biol Chem · November 5, 1989 Tissue factor is a lipoprotein, expressed on the surface of cells, which binds coagulation Factor VII or VIIa, leading to activation of Factors X and IX with subsequent fibrin generation. Cellular tissue factor activity is important in pathophysiologic pro ... Link to item Cite

Human mononuclear phagocyte transglutaminase activity cross-links fibrin.

Journal Article Thromb Res · July 1, 1989 The physiologic function of the monocyte transglutaminases is not known. In this study, we detected Factor XIII A-subunit antigen and "tissue" transglutaminase antigen in human monocytes by polyacrylamide gel electrophoresis and immunoblotting techniques. ... Full text Link to item Cite

Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function.

Journal Article Cancer Res · October 1, 1988 The purpose of this investigation was to understand the biological effects of recombinant human tumor necrosis factor used as therapy for cancer. We studied changes in mononuclear phagocyte function following exposure to this cytokine in vitro or in vivo. ... Link to item Cite

SPHINGOSINE INHIBITS TISSUE FACTOR-INDUCED BLOOD-CLOTTING

Journal Article ARTERIOSCLEROSIS · September 1, 1988 Link to item Cite

Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes.

Journal Article Blood · July 1988 The induction of procoagulant activity (PCA) by human recombinant tumor necrosis factor (rTNF) was studied in human monoblastic leukemia cell line U937 and human peripheral blood monocytes. Using a one-step recalcificating clotting assay, PCA in cell lysat ... Link to item Cite

Identification of normal human peripheral blood monocytes and liver as sites of synthesis of coagulation factor XIII a-chain.

Journal Article Blood · August 1987 Factor XIII is the fibrin-stabilizing factor that covalently cross-links fibrin monomers to form a highly organized, stable fibrin clot. The plasma form of factor XIII is a heterodimer, a2b2, consisting of two a-chains and two b-chains; the intracellular f ... Link to item Cite

TUMOR-NECROSIS-FACTOR INDUCES TISSUE FACTOR ACTIVITY IN HUMAN-LEUKEMIA CELL-LINE U937

Journal Article PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH · March 1, 1987 Link to item Cite

Brown blood: understanding methemoglobinemia.

Journal Article N C Med J · March 1986 Link to item Cite

Activation of monocyte and granulocyte antibody-dependent cytotoxicity by phorbol myristate acetate.

Journal Article Infect Immun · March 1982 We have characterized the effects of phorbol myristate acetate (PMA) on human monocyte and neutrophil oxidative metabolism and antibody-dependent cytotoxicity toward anti-D sensitized human erythrocytes (RBC) and a human lymphoblastoid cell line (CEM). Hex ... Full text Link to item Cite